Pelthos Therapeutics Inc. SEC Filings

Pelthos Therapeutics Inc. reported Q3 2025 results following its July 1 merger with LNHC and commercial launch of ZELSUVMI. Revenue reached $7.4 million, all generated in the quarter after launch. The company recorded a net loss of $16.2 million for Q3 and $21.7 million for the nine months ended September 30, 2025.

Cash and cash equivalents were $14.2 million as of September 30, 2025, with working capital of $25.0 million. Management disclosed “substantial doubt” about the ability to continue as a going concern, citing expected commercialization, manufacturing, and development costs. Total assets rose to $126.4 million, including $32.5 million of net definite-lived intangibles and $30.6 million of goodwill from the LNHC acquisition. SG&A was $19.6 million and cost of goods sold $2.3 million in Q3.

The company completed a PIPE concurrent with the merger, issuing 50,100 Series A preferred shares for gross proceeds of $50.1 million and net proceeds of $27.4 million after settlements; 23,810 preferred shares converted into 2,381,000 common shares. Common shares outstanding were 3,061,681 as of November 7, 2025.

Pelthos Therapeutics (PTHS) reported an insider transaction on a Form 4. On 11/06/2025, a reporting person identified as both a Director and 10% Owner acquired a senior secured convertible note with an aggregate principal amount of $9,000,000.

The note may be converted into common stock at a conversion price of $34.442 per share, corresponding to 261,309 underlying shares if fully converted. The instrument includes a beneficial ownership limitation of 49.9% with respect to the reporting person. The filing lists the security as acquired and directly owned.

Pelthos Therapeutics (PTHS): Ligand Pharmaceuticals filed Amendment No. 1 to Schedule 13D reporting the purchase of a $9.0 million senior secured convertible note from Pelthos on November 6, 2025. The note bears 8.5% interest, matures in 24 months, and is convertible at an initial $34.442 per share, subject to adjustments, including an automatic reduction to $29.73 on the later of December 1, 2025 and shareholder approval if then above that level. A 49.9% beneficial ownership cap limits conversions.

Ligand reports beneficial ownership of 1,500,000 common shares and 34,278.681 Series A Preferred (each convertible into 100 common shares), plus the convertible note; common shares outstanding were 3,042,143 as of August 8, 2025. Collateral includes specified revenue interests from Xepi and certain payments tied to ZELSUVMI. Investors receive a 5% royalty on Xepi net sales (Ligand’s share 2.5%). Pelthos agreed to file a resale registration within 60 days and target effectiveness as outlined, and amended Ligand’s lock-up through December 31, 2025 with 25% of shares released immediately.

Pelthos Therapeutics Inc. announced a private financing and product acquisition. The company completed a senior secured convertible note financing for gross proceeds of approximately $18.0 million. The notes bear 8.5% interest, mature on November 6, 2027, and are initially convertible at $34.442 per share, with an automatic reduction to $29.73 on the later of December 1, 2025 and shareholder approval, if then above that level. Beneficial ownership limits cap conversions to 49.9% for Ligand and 4.99% or 9.99% for other investors.

Investors also received a 5.0% royalty on net sales of Xepi and rights to certain Sato-related payments, and the notes are secured by a lien on specified revenue streams. Pelthos entered a registration rights agreement to file a resale registration within 60 days and seek effectiveness by 90 days or two business days after a no-review notice. Separately, Pelthos acquired the Xepi assets from Biofrontera for up to $10.0 million, including $3.0 million cash at closing, $1.0 million upon availability of commercial quantities, and contingent milestones, and signed an exclusive Ferrer/Interquim license and supply agreement for Xepi in the U.S. territory.

Pelthos Therapeutics Inc. (PTHS) furnished an investor presentation under Item 7.01 (Regulation FD) in a Form 8-K. The presentation, dated October 14, 2025, is attached as Exhibit 99.1 and was also made available on the company’s website. The company emphasizes that this information is being furnished, not filed, and therefore is not subject to Section 18 liabilities, nor is it incorporated by reference except as specifically stated.

The presentation includes forward-looking statements disclaimer language under the Private Securities Litigation Reform Act, covering topics such as commercialization progress, clinical development, market opportunities, intellectual property, and strategy execution. The filing reiterates that these statements involve risks and uncertainties and that the company undertakes no obligation to update them except as required by law.

Pelthos Therapeutics Inc. filed Amendment No. 1 to its shelf registration statement, described as an exhibits-only update. The change is limited to adding auditor consents from Ernst & Young LLP and BDO USA, P.C. as Exhibits 23.3 and 23.4, while the prospectus remains unchanged and is omitted from this amendment.

The filing also restates estimated issuance and distribution expenses, including an SEC registration fee of $26,400.78, and describes Nevada law and company charter provisions that limit director and officer liability and provide indemnification. Signature pages confirm authorization by the Chief Financial Officer and other officers and directors.

Pelthos Therapeutics filed an 8-K/A to amend its prior Current Report to attach unaudited condensed financial statements of LNHC, Inc. as of June 30, 2025 and 2024 and for the three- and six-month periods ended June 30, 2025 and 2024, plus unaudited pro forma condensed combined financial information for Pelthos for the six months ended June 30, 2025 and year ended December 31, 2024, in connection with the Merger. The amendment also attaches a schedule of material agreements and exhibits, including the Agreement and Plan of Merger, Securities Purchase Agreement, Registration Rights Agreement, various license and manufacturing agreements, and a Transition Services Agreement. The filing discloses beneficial ownership details showing a large holder with approximately 49.0% beneficial ownership and summarizes board composition, committee memberships, executive officers, and identified business risks including regulatory approval, supply-chain and commercialization concentration risks.

Pelthos Therapeutics Inc. is highlighting its story to investors by presenting at the Wells Fargo 2025 Healthcare Conference in Boston. The company’s Chief Executive Officer, Scott Plesha, and Chief Financial Officer, Francis Knuettel II, are scheduled to present on September 3, 2025, at 1:30 p.m. Eastern Time.

A live webcast and 90-day replay will be available on Pelthos’ website, giving investors access to management’s update on its product pipeline and recent business developments, including the commercial launch of ZELSUVMI. The company also furnished a press release and Q3 2025 presentation as exhibits, which include forward-looking statements about its launch execution, pipeline progress, intellectual property protection, and ability to carry out its development strategy amid various business and macroeconomic risks.

Pelthos Therapeutics Inc. files a shelf registration (Form S-3) registering shares to facilitate a private placement resale and other offerings while disclosing material risks and corporate arrangements. The company reports a going concern qualification from its auditors and notes it has incurred significant losses since inception. Commercial success depends heavily on ZELSUVMI, approved by the FDA in January 2024 and recently launched in the U.S., and on establishing effective sales, marketing and manufacturing capabilities. The prospectus details supply chain and manufacturing risks, limited experience producing commercial-scale product using the NITRICIL technology and API berdazimer sodium, intellectual property and litigation risks, regulatory and reimbursement uncertainties, and potential post-approval regulatory actions. The filing discloses equity instruments: 1,557,074 options, 515,520 RSUs, 5,500 warrants, and 327,406 reserved shares. The selling stockholder table identifies multiple PIPE participants and ownership assumptions used for percentage calculations.